Letrozole: present and future role in the treatment of breast cancer

Bibliography

• NADJI M, GOMEX-FERNANDEZ C, GANJEL-AZAR, MORALES AR: Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am. J. Clin. Pathol. (2005) 123(1):21-27.
   PubMed Web of Science ®Google Scholar
• Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group (EBCTG). Lancet (1998) 351(9114):1451-1467.
   PubMed Web of Science ®Google Scholar
• HAYES DF: Tamoxifen: Dr Jekyll and Mr. Hyde? J. Natl. Cancer Inst. (2004) 96(12):895-897.
   PubMedGoogle Scholar
• POWLES TJ, HICKISH T, KANIS JA, TIDY A, ASHLEY S: Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. (1996) 14(1):78-84.
   PubMed Web of Science ®Google Scholar
• HARADA N, UTSUMI T, TAKAGI Y: Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinoogenesis. Proc. Natl. Acad. Sci. USA (1993) 90(23):11312-11316.
   PubMed Web of Science ®Google Scholar
• ZHAO Y, NICHOLS JE, BULUN SE, MENDELSON CT, SIMPSON ER: Aromatase P450 gene expression in human adipose tissue. Role of a Jak/STAT pathway in regulation of the adipose-specific promoter. J. Biol. Chem. (1995) 270(27):16449-16457.
   PubMed Web of Science ®Google Scholar
• KARAER O, ORUC S, KOYUNCU FM: Aromotase inhibitors: possible future applications. Acta Obstet. Gynecol. Scand. (2004) 83(8):699-706.
   PubMed Web of Science ®Google Scholar
• NAKATA T, TAKASHIMA S, SHIOTSU Y et al.: Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. J. Steroid Biochem. Mol. Biol. (2003) 86(3-5):455-460.
   PubMed Web of Science ®Google Scholar
• OSBORNE CK: Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. (1998) 339(22):1609-1618.
   PubMed Web of Science ®Google Scholar
• SMITH IE, DOWSETT M: Aromatase inhibitors in breast cancer. N. Engl. J. Med. (2003) 348(24):2431-2442.
   PubMed Web of Science ®Google Scholar
• Femara®: Letrozole tablets package insert. Novartis (2001); Jan (T2001-03):8901032.
   Google Scholar
• MITWALLY MF, CASPER RF: Aromatase inhibition for ovarian stimulation: future avenues for infertility management. Curr. Opin. Obstet. Gynecol. (2002) 14(3):225-263.
   Google Scholar
• STEIN RC, DOWSETT M, HEDLEY A, GAZET JC, FORD HT, COOMBES RC: The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br. J. Cancer (1990) 62(4):679-683.
   PubMed Web of Science ®Google Scholar
• DOWSETT M, STEIN RC, COOMBES RC: Aromatization inhibition alone or in combination with FnRH agonists for the treatment of premenopausal breast cancer patients. J. Steroid Biochem. Mol. Biol. (1992) 43(1-3):155-159.
   PubMed Web of Science ®Google Scholar
• CELIO L, MARTINETTI A, FERRARI L et al.: Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res. (1999) 19(3B):2261-268.
   PubMed Web of Science ®Google Scholar
• JEE BC, KU SY, SUH CS, KIM KC, LEE WD, KIM SH: Use of letrozole versus clomiphene citrate combined with gonadotropins in intrauterine insemination cycles: a pilot study. Fertil. Steril. (2006) 85(6):1774-1777.
   PubMed Web of Science ®Google Scholar
• VERPOEST WM, KOLIBIANAKIS E, PAPANIKOLAOU E, SMITZ J, VAN STEIRTEGHEM A, DEVROEY P: Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study. Reprod. Biomed. Online (2006) 13(2):166-172.
   PubMed Web of Science ®Google Scholar
• AL-FADHLI R, SYLBESTRE C, BUCKETT W, TAN SL, TULANDI T: A randomized trial of superovulation with two different doses of letrozole. Fertil. Steril. (2006) 85(1):161-164.
   PubMed Web of Science ®Google Scholar
• ATAY V, CAM C, MUCHU M, CAM M, KARATEKE A: Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J. Int. Med. Res. (2006) 34(1):73-76.
   PubMed Web of Science ®Google Scholar
• BEGUM MR, QUADIR E, BEGUM A, BEGUM RA, BEGUM M: Role of aromatase inhibitor in ovularion induction in patients with poor response to clomiphene citrate. J. Obstet. Gynaecol. Res. (2006) 32(5):502-506.
   PubMed Web of Science ®Google Scholar
• OKTAY K, HOURVITZ A, SAHIN G et al.: Letrozole reduces estrogen and gonadotropins exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J. Clin. Endocrinol. Metab. (2006) 91(10):3885-3890.
   PubMed Web of Science ®Google Scholar
• SCOTT LJ, KEAM SJ: Letrozole: in postmenopausal hormone-responsive early-stage breast cancer. Drugs (2006) 66(3):353-362.
   PubMed Web of Science ®Google Scholar
• LONNING P: Clinical pharmacokinetics of aromatase inhibitors and inactivators. Clin. Pharmacokinet. (2003) 42(7):619-631.
   PubMed Web of Science ®Google Scholar
• DOWSETT M, SMITH IE, EBBS SR et al.: Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin. Cancer Res. (2006) 12(3 Suppl.):S1024-S1030.
   PubMed Web of Science ®Google Scholar
• INGLE JN, SUMAN VJ, JOHNSON PA et al.: Evaluation of tamozifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin. Cancer Res. (1999) 5(7):1642-1649.
   PubMed Web of Science ®Google Scholar
• GEISLER J, HAYNES B, ANKER F, DOWSETT M, LONNING PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. (2002) 20(3):751-757.
   PubMed Web of Science ®Google Scholar
• ROSE C, VTORAYA O, PLUZANSKA A et al.: An open randomized trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer (2003) 39(16):2318-2327.
   PubMed Web of Science ®Google Scholar
• DIXON JM, RENSHAW L, YOUNG O et al.: Anastrozole and letrozole an investigation and comparison of quality of life, tolerability and morbidity. Breast Cancer Res. Treat. (2006) 100(Suppl. 1):A105.
   Google Scholar
• DOMBERNOWSKY P, SMITH I, FALKSON G et al.: Letrozole a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. (1998) 16(2):453-461.
   PubMed Web of Science ®Google Scholar
• BUDZAR A, DOUMA J, DAVIDSON N et al.: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. (2001) 19(14):3357-3366.
   PubMed Web of Science ®Google Scholar
• MOURIDSEN H, GERSHANOVICH M, SUN Y et al.: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. (2003) 21(11):2101-2109.
   PubMed Web of Science ®Google Scholar
• MARCOM PK, ISAACS C, HARRIS L et al.: A phase II trial of letrozole and trastuzumab for ER and/or PR and HER2 positive metastatic breast cancer: final results. Proc. Am. Soc. Clin. Oncol. (2005) 23(16S):S27 (Abstract # 596).
   Google Scholar
• TRAINA TA, RUGO H, CARAVELLI J et al.: Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):S133 (Abstract # 3050).
   Web of Science ®Google Scholar
• FISHER B, DIGNAM J, BRYANT J et al.: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. (1996) 88(21):1529-1542.
   PubMed Web of Science ®Google Scholar
• GOSS PE, INGLE JN, MARTINO S et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. (2003) 349(19):1793-1802.
   PubMed Web of Science ®Google Scholar
• INGLE J, TU D, SHEPHERD L, PALMER M, PATER J, GOSS P: NCIC CTG MA.17: intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):A549.
   PubMed Web of Science ®Google Scholar
• GOSS PE, INGLE JN, MARTINO S et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. (2005) 97(17):1262-1271.
   PubMed Web of Science ®Google Scholar
• WASAN KM, GOSS PE, PRITCHARD PH et al.: The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann. Oncol. (2005) 16(5):707-715.
   PubMed Web of Science ®Google Scholar
• PEREZ EA, JOSSE RG, PRITCHARD KI et al.: Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a comparison study to NCIC CTG MA.17. J. Clin. Oncol. (2006) 24(22):3629-3635.
   PubMed Web of Science ®Google Scholar
• COATES AS, KESHAVIAH A, THÜRLIMANN B et al.: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. (2007) 25(5):486-492.
   PubMed Web of Science ®Google Scholar
• WINER EP, HUDIS C, BURSTEIN HJ et al.: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. (2005) 23(3):619-629.
   PubMed Web of Science ®Google Scholar
• GOLDHIRSCH A, GLICK JH, GELBER RD, COATES AS, THÜRLIMANN B, SENN HJ: Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann. Oncol. (2005) 16(10):1569-1583.
   PubMed Web of Science ®Google Scholar
• EIERMANN W, PAEPKE S, APPFELSTAEDT J et al.: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. (2001) 12(11):1527-1532.
   PubMed Web of Science ®Google Scholar
• ELLIS MJ, COOP A, SINGH B et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErB-1- and/or ErbB-2 positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. (2001) 19(18):3808-3816.
   PubMed Web of Science ®Google Scholar
• RENSHAW L, MURRAY J, YOUNG O, CAMERON D, MILLER WR, DIXON JM: Is there an optimal duration of neoadjuvant letrozole therapy? Breast Cancer Res. Treat. (2004) 88(Suppl. 1):S36(Abstract # 405).
   Google Scholar
• GUILLEM V, LLOMBART-CUSSAC A, GUERRERO JL et al.: Clinical response at 4 months to neoadjuvant letrozole predicts distant disease free survival in postmenopausal women with stage II – III ER/PgR-positive breast cancer. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):10531.
   Google Scholar
• MACASKILL EJ, RENSHAW L, DIXON JM: Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer. Oncologist (2006) 11(10):1081-1088.
   PubMed Web of Science ®Google Scholar
• ELLIS MJ, TAO Y, YOUNG O et al.: Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J. Clin. Oncol. (2006) 24(19):3019-3025.
   PubMed Web of Science ®Google Scholar
• BOYCE SP, MINCEY BA, DUH MS et al.: Risk of osteoporosis/osteopenia among women with breast cancer receiving anti-cancer therapy (ACT). Proc. Am. Soc. Clin. Oncol. (2005) 23(16S):S44 (Abstract # 665).
   Google Scholar
• MINCEY BA: Osteoporosis in women with breast cancer. Curr. Oncol. Rep. (2003) 5(1):53-57.
   PubMedGoogle Scholar
• FALLOWFIELD L: Acceptance of adjuvant endocrine therapies and quality of life issues. Breast (2005) 14(6):612-616.
   PubMed Web of Science ®Google Scholar
• WHELAN TJ, GOSS PE, INGLE JN et al.: Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J. Clin. Oncol. (2005) 23(28):6931-6940.
   PubMed Web of Science ®Google Scholar
• BRUFSKY A, HARKER WG, BECK JT et al.: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J. Clin. Oncol. (2006) 25(7):829-836.
   Google Scholar
• YANCIK R, WESLEY MN, RIES LA, HAVLIK RJ, EDWARDS BK, YATES JW: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. Jama (2001) 285(7):885-892.
   PubMed Web of Science ®Google Scholar
• FRANKLIN SS, GUSTIN W, WONG ND et al.: Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation (1997) 96(1):308-315.
   PubMed Web of Science ®Google Scholar
• NILSSON G, HOLMBERG L, GARMO H, TERENT A, BLOMQVIST C: Increased incidence of stroke in women with breast cancer. Eur. J. Cancer (2005) 41(3):423-429.
   PubMed Web of Science ®Google Scholar
• MCCLOSKEY E, EASTELL R, LAKNER G, MIYAMOTO A, CLACK G: Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res. Treat. (2005) 94(Suppl. 1):S101 (Abstract # 2052).
   Google Scholar
• BACHMANN GA: Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. J. Reprod. Med. (2005) 50(3):155-165.
   PubMed Web of Science ®Google Scholar
• STAROPOLI CA, FLAWS JA, BUSH TL, MOULTON AW: Predictors of menopausal hot flashes. J. Womens Health (1998) 7(9):1149-1155.
   PubMed Web of Science ®Google Scholar
• PANDIT L, OUSLANDER JG: Postmenopausal vaginal atrophy and atrophic vaginitis. Am. J. Med. Sci. (1997) 314(4):228-231.
   PubMed Web of Science ®Google Scholar
• THURLIMANN B, KESHAVIAH A, COATES AS et al.: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. (2005) 353(26):2747-2757.
   PubMed Web of Science ®Google Scholar
• THOMAS RJ, MARSHALL CJ, WILLIAMS M, WALKER LG: Does switching to letrozole improve hot flushes, mood and quality of life in tamoxifen intolerant patients? Breast Cancer Res. Treat. (2005) 94(Suppl. 1):S107 (Abstract # 2067).
   Google Scholar
• BOTTINI A, GENERALI D, BERUTI A et al.: Primary letrozole therapy versus the combination of letrozole plus oral cyclophosphamide in elderly breast cancer patients: a single institution randomized phase II trial. Proc. Am. Soc. Clin. Oncol. (2005) 23(16S):S756 (Abstract # 8108).
   Google Scholar
• RADICE D, REDAELLI A: Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics (2003) 21(6):383-396.
   PubMed Web of Science ®Google Scholar
• BERKOWITZ N, GUPTA S, SILBERMAN G: Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health (2000) 3(1):23-30.
   PubMedGoogle Scholar
• KARNON J, JOHNSTON SR, JONES T, GLENDENNING A: A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. Ann. Oncol. (2003) 14(11):1629-1633.
   PubMed Web of Science ®Google Scholar
• KARNON J, DELEA T, JOHNSTON SR et al.: Cost-effectiveness of letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics (2006) 24(3):237-250.
   PubMed Web of Science ®Google Scholar
• OUAGARI KE, KARNON J, DELEA T, TALBOT W, BRANDMANN J: Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res. Treat. (2007) 101(1):37-49.
   PubMed Web of Science ®Google Scholar
• DRANITSARIS G, VERMA S, TRUDEA M: Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am. J. Clin. Oncol. (2003) 26(3):289-296.
   PubMed Web of Science ®Google Scholar
• DUNN C, KEAM SJ: Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer. Pharmacoeconomics (2006) 24(5):495-517.
   PubMed Web of Science ®Google Scholar
• DELEA TE, KARNON J, SMITH RE et al.: Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am. J. Manag. Care (2006) 12(7):374-386.
   PubMed Web of Science ®Google Scholar
• DELEA TE, KARNON J, THOMAS SK et al.: Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a US perspective. Breast Cancer Res. Treat. (2005) 94(Suppl. 1):S102 (Abstract # 2054).
   Google Scholar